Boston Scientific Recalls Spinal Cord Stimulator Leads After Injury Reports

Key Facts

In a move highlighting safety challenges within the medical device sector, Boston Scientific has initiated a recall of its Infinion CX Spinal Cord Stimulator (SCS) leads. This decision follows 1,081 reports of injuries linked to lead fractures, prompting health authorities to demand the immediate return of all unused inventory. According to reports, the recall is a corrective measure to mitigate physical risks posed to patients by these technical failures.

These developments emerge at a critical time for the company, as product recalls involving over a thousand injury reports typically escalate litigation risks and potential market share erosion in the competitive medical technology segment. Per market data, the company's stock (0HOY.L) closed at $47.24 on September 3, 2026, having traded between a day low of $46.98 and a high of $49.17.

Traders should monitor the current support level at $46.98 (as of September 3, 2026 close) to gauge market reaction to potential legal liabilities. With no major upcoming economic catalysts directly impacting the sector in the immediate calendar, focus remains on further updates from health authorities regarding the scale of the recall and its operational impact on the firm.